Pharma Veteran’s Move to AI Biotech Signals Major Industry Shift

AMSTERDAM and ZURICH – March 03, 2026 – In a move that underscores a significant inflection point for the pharmaceutical industry, renowned drug discovery leader Marcus Schindler has joined the advisory board of AI protein engineering firm Cradle. Schindler, who until recently served as the Chief Scientific Officer at the pharma giant Novo Nordisk, brings decades of high-level R&D experience to the rapidly growing biotech platform, signaling a powerful convergence of legacy expertise and next-generation technology.

The appointment is more than a high-profile hire; it's a potent symbol of the shifting dynamics in drug discovery. As large pharmaceutical companies grapple with integrating artificial intelligence into their complex and heavily regulated workflows, the decision by a top-tier executive to align with an external AI platform is a major validation of that platform's approach and potential.

"Marcus is renowned for modernizing drug discovery at some of the world's largest pharmaceutical companies," said Stef van Grieken, co-founder and CEO of Cradle. "He has been transformative in building thriving cultures that turn technology into a genuine competitive advantage... We're excited to work closely with Marcus and draw on his deep experience driving R&D innovation to apply AI in practical, meaningful ways."

The Talent Endorsement: Bridging Pharma and AI

Marcus Schindler's career is a map of modern pharmaceutical innovation. During his tenure as CSO at Novo Nordisk, he was a key architect in transforming the company's research efforts, expanding its focus into new therapeutic areas like cardiovascular disease and strengthening collaborations to access emerging technologies. His leadership was marked by a push towards digitalization and the adoption of machine learning, a journey he has described as moving from simply digitizing lab notebooks to developing a comprehensive AI strategy.

His move to advise Cradle is a testament to the growing belief that specialized AI firms may hold the key to unlocking the next wave of therapeutic breakthroughs. Schindler himself highlighted the core challenge facing his former peers in big pharma.

"I've seen over the course of my career that a major challenge for large pharma is to integrate AI solutions directly into complex, established R&D workflows in a way that actually empowers and augments scientists," Schindler stated. He praised Cradle for appreciating "the reality of complex drug discovery" and delivering "robust, reliable and repeatable results for scientists at the bench."

This endorsement from an industry insider who has navigated these integration challenges firsthand suggests that the future of pharmaceutical R&D may not be about large companies building all their AI capabilities from scratch. Instead, it points to a more symbiotic model where they partner with specialized technology providers who have already honed their platforms.

A New Blueprint for R&D: The SaaS Advantage

At the heart of Cradle's appeal is its business model: a traditional Software-as-a-Service (SaaS) platform. This approach directly addresses some of the most significant hurdles for AI adoption in the biopharma world, particularly intellectual property (IP) protection and workflow integration.

Instead of engaging in complex, one-off collaborations that can blur the lines of IP ownership, Cradle's platform allows a company's own scientists to use its powerful AI tools directly. This enables pharma giants to leverage cutting-edge generative AI for protein engineering—designing novel antibodies, enzymes, peptides, and vaccines—while retaining all rights to the assets they develop. This model effectively resolves the classic "build vs. buy" dilemma, offering a third way: subscribe and empower.

This strategy has proven highly successful. Cradle's platform is already being used in over 50 protein R&D programs worldwide, with the company counting six of the top 25 global biopharma organizations as partners, including Johnson & Johnson, AbbVie, and Schindler's former employer, Novo Nordisk. Earlier this year, Cradle announced a major partnership with Bayer to accelerate antibody discovery, a deal that was finalized after a successful proof-of-concept project demonstrated the platform's capabilities.

From Hype to Quantifiable Impact

For years, the promise of AI in drug discovery was more theoretical than tangible. Now, companies like Cradle are delivering measurable results that command the attention of R&D leaders and chief financial officers alike. Customers report that using the platform can accelerate early research and development timelines by a factor of two to twelve times.

This dramatic speedup is achieved by using AI to predict the properties of novel proteins in silico (on a computer), drastically reducing the number of costly and time-consuming wet lab experiments required to find a promising candidate. By generating better candidates faster, the platform not only accelerates discovery but also drives significant cost efficiencies. In one documented case, a biotech customer used Cradle to revive a stalled project, successfully engineering an enzyme four times more active in just three experimental rounds, a feat that had been impossible over the previous ten rounds.

This ability to move beyond pilot programs to scalable, repeatable applications is what Schindler identified as a key differentiator for Cradle. The platform is not just an academic exercise; it is a robust industrial tool that is already being deployed across a diverse range of programs, helping scientists engineer everything from new therapeutics to more efficient bio-based materials.

The New Collaborative Ecosystem of Drug Discovery

The trend of external AI collaborations is reshaping the entire biopharma innovation landscape. Industry analysis shows a massive surge in partnerships between AI vendors and pharmaceutical companies over the past decade. This shift is driven by the recognition that the pace of AI development is too rapid for any single company, no matter how large, to keep up with internally.

While challenges in AI integration remain—including data quality, regulatory compliance, and a persistent talent gap—specialized firms are emerging to provide targeted solutions. By focusing on a specific, critical part of the drug discovery pipeline like protein engineering, companies like Cradle can develop deep expertise and a refined product that is easier for large organizations to adopt.

Schindler's decision to join Cradle's advisory board is a powerful indicator of this new reality. It shows that the road to the next generation of medicines will likely be paved not by monolithic, self-contained R&D empires, but by a dynamic and collaborative ecosystem where the most experienced minds in pharma work hand-in-hand with the most innovative minds in technology.